Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis

Keyphrases

• Fibrosis 100%
• Tissue Damage 100%
• CD8+ T Cells 100%
• Virus Control 100%
• Anti-PD-1 Immunotherapy 100%
• Chronic Virus Infection 100%
• T Cell Activation 66%
• Reinvigoration 66%
• Checkpoint Inhibitors 66%
• Tumor 33%
• Immunopathology 33%
• Pathological Changes 33%
• T Cells 33%
• Immunotherapeutics 33%
• Physiological Processes 33%
• Pathogenicity 33%
• T Cell Exhaustion 33%
• Virus Load 33%
• Infected Mice 33%
• Virus-infected Cell 33%
• T-cell Mediated 33%
• Chronic Lymphocytic 33%
• Lymphocytic Choriomeningitis Virus 33%
• Spleen Fibrosis 33%
• Anti-PD-L1 Antibody 33%

Immunology and Microbiology

• Viral Disease 100%
• Cytotoxic T-Cell 100%
• Virus 100%
• Programmed Death-Ligand 1 100%
• Immunotherapy 100%
• Viral Load 33%
• Lymphocytic Choriomeningitis Virus 33%
• T Cell 33%
• Pathogenicity 33%
• Physiological Process 33%
• Immunopathology 33%
• Infancy 33%
• T Cell Exhaustion 33%